The decision to open new headquarters in Mills River, North Carolina, was made at the end of 2014. We broke ground in March of 2015, and just nine months later we were able to move into the new building. A two-story production and administration building with a total area of 60,000 ft² (5,600 m²) serves as a production and development center for customer-specific polymer components and systems, including 13,000 ft² (1,200 m²) of the most cutting-edge clean room production according to ISO class 7.
RAUMEDIC Inc. in Mills River started production in January 2016 with 56 employees. Specialists in the fields of engineering, research and development, clean room production, quality management, logistics, marketing and sales, as well as management have settled into their new workplace. The order books have filled up nicely and the number of new employees will increase in the coming months.
Not only is the architecture reminiscent of the German headquarters, but also the technology, quality and services as a polymer specialist for the medical engineering and pharmaceutical industry. High-quality polymer products will be custom developed, produced and packaged at both locations, the German plant and the new US location. CEO Martin Bayer: “This is an important step for RAUMEDIC. We will now offer our customers the same quality and service they have come to expect from us as a development partner and system supplier at the Mills River location in the USA.”
This includes multi-component injection molding with hard-hard and hard-soft connections, micro injection molding, insert molding, fully automated assembly systems, micro extrusion with an internal diameter of 0.1 mm and multiple layers in the tubing wall including X-ray tubing or film blowing. These are advanced technologies that will be introduced gradually at the new Mills River plant.
Based on decades of expertise in chemistry and raw materials, RAUMEDIC processes all current medical-grade thermoplastics, silicones and high temperature polymers such as PEEK, FEP or PTFE. The ability to do our own compounding for customized material formulas rounds off our portfolio.
Until now, medical products manufactured in Germany were sold in the USA by RAUMEDIC Inc. Rudi Gall, Managing Director RAUMEDIC Inc.: “With our new development and production center, we are able to combine the strengths of both German and American engineering. The advantages are obvious: short routes and a more comprehensive as well as timely service for our North American customers.”
RAUMEDIC has invested approximately 11 million US dollars in the construction of the modern building. A total investment of approximately 27 million US dollars will be reached by 2022.
The official dedication of the building will take place on April 22, 2016 and thus the company continues its story of success. The polymer processing company is steadily pursuing its path of expansion and meeting the challenges of the largest and most innovative medical market in the world. Thanks to its development expertise and manufacturing technologies, RAUMEDIC is optimally equipped for this challenge.